Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Cost and Value of Anti-Epidermal Growth Factor Receptor Therapies: Let's Not Be Rash.

JAMA oncology - 1 May 2015

Saltz Leonard B

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cost-Benefit Analysis
Share to Disease-Free Survival
Share to Drug Costs
Share to Exanthema

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Targeted Therapy

Share to Patient Selection

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 26181010
DOI: 10.1001/jamaoncol.2015.0287

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Cost and Value of Anti-Epidermal Growth Factor Receptor Therapies: Let's Not Be Rash.PMID 26181010Read ↗

Dermatological adverse effects during genotype-1 hepatitis C treatment with the protease inhibitors telaprevir and boceprevir. Patient management.Semantic proximity Read ↗

[Perspectives and future developments of epidermal growth factor receptors inhibitors].Semantic proximity Read ↗

Not just a childhood rash: Treating atopic dermatitis in older people.Semantic proximity Read ↗

Patients who do not respond to the "usual" dose: why Terry fell off the dose-response curve.Semantic proximity Read ↗

Patient Characteristics and Individualization of Biologic Therapy.Semantic proximity Read ↗

NSAIDs and Kelleni’s protocol as potential early COVID-19 treatment game changer: could it be the final countdown?Semantic proximity Read ↗

Patient Perspective—Where Does the Value for Money of a Treatment Really Lie?Semantic proximity Read ↗

Methodological Challenges in Dutch HTA of Non-Oncological Orphan Drugs: A Retrospective Analysis and Price Comparison Using different Pricing ModelsSemantic proximity Read ↗

Clinical setbacks for toll-like receptor 9 agonists in cancerSemantic proximity Read ↗

Is HLA-B*58:01 genotyping cost effective in guiding allopurinol use in gout patients with chronic kidney disease?Semantic proximity Read ↗

Guiding the willingness to pay for repurposed tiratricol in the treatment of Allan-Herndon-Dudley syndrome using a cost-based-plus pricing frameworkSemantic proximity Read ↗

Cost-effectiveness analysis of HLA-B5801 genotyping in the treatment of gout patients with chronic renal insufficiency in Korea.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.